Lenalidomide Capsule
Product Images NDC 73043-039

This description is of a medication called Lenalidomide, which comes in capsule form and is used for a specific condition. The text emphasizes a warning about the potential for human birth defects, and instructions are given regarding storage and administration of the medication. The medication is to be kept out of the reach of children. The text also indicates that the capsules contain 10 mg of Lenalidomide each, with 100 capsules available in the pack. Details about the manufacturer and lot number are provided as well.*

This is a description of Lenalidomide Capsules, a medication used under prescription only due to its warning regarding the potential for human birth defects. The capsules come in a package containing 100 capsules, with each capsule containing 20 mg of lenalidomide. They must be stored at a temperature between 20°C and 25°C, with excursions permitted to 15°C to 30°C (59°F to 77°F). The medication should be kept out of reach of children. The packaging includes administrative information and instructions, indicating the potential risks and storage requirements of the medication. The capsules are made in Turkey and distributed by Devatis Inc in San Clemente, CA. The packaging also displays specific details like the expiration date, size of the capsules, and a product code.*

This is information about Lenalidomide Capsules with a warning about potential human birth defects. The capsules contain 25 mg of lenalidomide each and should be stored at controlled room temperature. The packaging includes 100 capsules. The text also mentions a prescribing guide and emphasizes keeping all medicines out of the reach of children. The product is manufactured in Turkey and distributed by Devatis Inc in San Clemente, CA. The label includes various codes and measurements such as 77x63x110 mm.*

This is not available.*

This description pertains to the comparison of survival probability between a treatment group receiving Lenalidomide and a control group receiving a placebo. The hazard ratio (HR) with its corresponding confidence interval (CI) and Kaplan-Meier median values are reported. Additionally, information on progression-free survival in months is provided, along with the number of subjects at risk. The analysis suggests that Lenalidomide may offer a statistically significant benefit in terms of survival compared to the placebo group.*

This text provides information on the proportion of subjects in a study comparing Lenalidomide/Dex to Placebo/Dex, showing a significant difference in progression-free survival. The hazard ratio (HR) with its 95% confidence interval is 0.285 (0.210-0.366) with a p-value of less than 0.001 based on the Log Rank test. The graph displays the time to progression in months, with a cutoff at around 20 months where a notable difference between the two treatment groups can be observed. This data suggests that the Lenalidomide/Dex combination may be more effective in delaying disease progression compared to the placebo and dexamethasone combination.*

This information provides data on the proportion of subjects and the results of a study involving lenalidomide/dex versus placebo/dex. The hazard ratio (HR) is 0.324 (95% CI 0.240-0.438) with a significant p-value of less than 0.001 based on the log-rank test. The graph displays the time to progression in months.*